Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | FHD-286 |
Synonyms | |
Therapy Description |
FHD-286 inhibits SMARCA4 (BRG1) and SMARCA2 (BRM), which may lead to altered chromatin accessibility and decreased tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr ND14, PMID: 38437498). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
FHD-286 | FHD286|FHD 286 | FHD-286 inhibits SMARCA4 (BRG1) and SMARCA2 (BRM), which may lead to altered chromatin accessibility and decreased tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr ND14, PMID: 38437498). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KMT2A rearrange | acute myeloid leukemia | sensitive | FHD-286 | Preclinical - Patient cell culture | Actionable | In a preclinical study, FHD-286 induced differentiation and decreased viability in acute myeloid leukemia cell lines and patient-derived cells harboring a KMT2A rearrangement in culture (PMID: 38437498). | 38437498 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04891757 | Phase I | FHD-286 | FHD-286 in Subjects With Advanced Hematologic Malignancies | Recruiting | USA | 0 |
NCT04879017 | Phase I | FHD-286 | FHD-286 in Subjects With Metastatic Uveal Melanoma | Terminated | USA | NLD | FRA | 0 |